BRPI0414443A - imunógenos consensuais/ancestrais - Google Patents

imunógenos consensuais/ancestrais

Info

Publication number
BRPI0414443A
BRPI0414443A BRPI0414443-0A BRPI0414443A BRPI0414443A BR PI0414443 A BRPI0414443 A BR PI0414443A BR PI0414443 A BRPI0414443 A BR PI0414443A BR PI0414443 A BRPI0414443 A BR PI0414443A
Authority
BR
Brazil
Prior art keywords
immunogen
consensual
immunogens
inducing
immune response
Prior art date
Application number
BRPI0414443-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Bette T Korber
Beatrice H Hahn
George M Shaw
Denise Kothe
Ying Ying Li
Julie Decker
Original Assignee
Univ Duke
Univ Alabama Res Found
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Duke, Univ Alabama Res Found, Univ California filed Critical Univ Duke
Publication of BRPI0414443A publication Critical patent/BRPI0414443A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4216—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-viral Ig
    • C07K16/4225—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-viral Ig against anti-HIV Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BRPI0414443-0A 2003-09-17 2004-09-17 imunógenos consensuais/ancestrais BRPI0414443A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50346003P 2003-09-17 2003-09-17
US60472204P 2004-08-27 2004-08-27
PCT/US2004/030397 WO2005028625A2 (en) 2003-09-17 2004-09-17 Consensus/ancestral immunogens

Publications (1)

Publication Number Publication Date
BRPI0414443A true BRPI0414443A (pt) 2006-11-21

Family

ID=34381074

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0414443-0A BRPI0414443A (pt) 2003-09-17 2004-09-17 imunógenos consensuais/ancestrais

Country Status (10)

Country Link
US (3) US8071107B2 (https=)
EP (2) EP1667714B1 (https=)
JP (3) JP4773352B2 (https=)
KR (2) KR20070028291A (https=)
CN (2) CN102010463A (https=)
AU (1) AU2004274937B9 (https=)
BR (1) BRPI0414443A (https=)
CA (2) CA2539325C (https=)
IL (3) IL174380A0 (https=)
WO (1) WO2005028625A2 (https=)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1307130A4 (en) 2000-02-04 2005-01-12 Beth Israel Hospital VACCINE AGAINST THE VIRUS OF HUMAN IMMUNODEFICIENCY
EP1331942A4 (en) 2000-09-22 2005-03-16 Univ Duke Immunogenic with ligand-bound HIV envelope protein
US7033593B2 (en) 2000-09-22 2006-04-25 Duke University Immunogen comprising an HIV envelope protein, a ligand and H2 peptide
CA2539325C (en) 2003-09-17 2016-03-22 Duke University Consensus/ancestral immunogens
US8048431B2 (en) * 2003-09-17 2011-11-01 Duke University Modified HIV-1 clade C envelope glycoprotein immunogens comprising deletions in the gp120/gp41 cleavage site and gp41 fusion domain
EP2309269B1 (en) 2004-09-08 2016-10-26 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Compositions and methods for the detection of HIV-1/HIV-2 infection.
CN101969996A (zh) * 2005-08-23 2011-02-09 加利福尼亚大学董事会 多价疫苗
US7951377B2 (en) * 2005-08-23 2011-05-31 Los Alamos National Security, Llc Mosaic clade M human immunodeficiency virus type 1 (HIV-1) envelope immunogens
SG170092A1 (en) * 2006-03-10 2011-04-29 Peptcell Ltd Peptides of regulatory or accessory proteins of hiv, compositions and the utilization thereof
EP2001459B1 (en) * 2006-03-29 2012-07-11 Dana-Farber Cancer Institute, Inc. Methods and compositions for inducing an immune response to hiv and models for testing
CA2654324A1 (en) * 2006-06-02 2007-12-13 International Aids Vaccine Initiative Hiv-1 clade a consensus sequences, antigens, and transgenes
AU2007278831B2 (en) * 2006-07-28 2013-03-21 The Trustees Of The University Of Pennsylvania Improved vaccines and methods for using the same
AU2015234338C1 (en) * 2006-07-28 2017-07-20 The Trustees Of The University Of Pennsylvania Improved vaccines and methods for using the same
JP2010530356A (ja) * 2007-03-27 2010-09-09 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 急性伝染ｈｉｖエンベロープ・サイン
WO2010059732A1 (en) 2008-11-18 2010-05-27 Beth Israel Deaconess Medical Center Antiviral vaccines with improved cellular immunogenicity
WO2011106100A2 (en) 2010-02-25 2011-09-01 Duke University Method of inducing the production of protective anti-hiv-1 antibodies
AU2011221549A1 (en) * 2010-03-03 2012-11-01 Duke University Molecular clone of HIV-1
US20130273103A1 (en) * 2010-09-28 2013-10-17 Los Alamos National Security, Llc Polyvalent immunogen
EP2492279A1 (en) * 2011-02-25 2012-08-29 Laboratorios Del. Dr. Esteve, S.A. Rapid immunogen selection method using lentiviral display
EP2739300B1 (en) 2011-07-05 2019-06-19 Duke University N-terminal deleted gp120 immunogens
CA2850745C (en) * 2011-10-03 2022-12-13 Duke University Vaccine
EP2620446A1 (en) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
WO2013131099A1 (en) 2012-03-02 2013-09-06 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of altering the immundominance hierarchy of hiv gag by dna vaccine expressing conserved regions
KR20150036593A (ko) * 2012-07-24 2015-04-07 사노피 파스퇴르 뎅기열 바이러스 감염 예방용 백신 조성물
KR101826536B1 (ko) 2012-08-07 2018-02-07 현대자동차 주식회사 차량의 아이들 스톱 제어 방법 및 장치
WO2014151687A2 (en) 2013-03-15 2014-09-25 University Of Massachusetts Compositions and methods to treat aids
US9920305B2 (en) * 2013-10-16 2018-03-20 New England Biolabs, Inc. Reverse transcriptase with enhanced properties
MA40783A (fr) * 2014-10-03 2017-08-08 Los Alamos Nat Security Llc Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population
WO2017007646A1 (en) * 2015-07-07 2017-01-12 International Aids Vaccine Initiative Hiv-1 clade c envelope glycoproteins
US11318197B2 (en) 2016-03-03 2022-05-03 Duke University Compositions and methods for inducing HIV-1 antibodies
US11246920B2 (en) 2016-03-03 2022-02-15 Duke University Compositions and methods for inducing HIV-1 antibodies
AR109528A1 (es) * 2016-09-15 2018-12-19 Janssen Vaccines & Prevention Bv Mutaciones estabilizantes de trímeros de proteínas de la envoltura del vih
US10828363B1 (en) * 2016-09-16 2020-11-10 The Trustees Of The University Of Pennsylvania Extreme polyvalency induces potent cross-clade cellular and humoral responses in rabbits and non-human primates
EP3519428A4 (en) 2016-10-03 2020-07-08 Duke University METHODS OF IDENTIFYING IMMUNOGENS BY TARGETING IMPROBABLE MUTATIONS
US11230572B2 (en) 2016-10-17 2022-01-25 Beth Israel Deaconess Medical Center, Inc. Signature-based human immunodeficiency virus (HIV) envelope (Env) trimer vaccines and methods of using the same
US12138304B2 (en) 2018-10-01 2024-11-12 Duke University HIV-1 envelope stabilizing mutations
GB201816873D0 (en) * 2018-10-17 2018-11-28 Imperial Innovations Ltd Fusion protein
CN114761041A (zh) 2019-07-16 2022-07-15 吉利德科学公司 Hiv疫苗及其制备和使用方法
CA3161633A1 (en) 2019-11-14 2021-05-20 Aelix Therapeutics, S.L. Dosage regimens for vaccines
EP4277652A1 (en) 2021-01-14 2023-11-22 Gilead Sciences, Inc. Hiv vaccines and methods of using
US20250213675A1 (en) * 2022-03-31 2025-07-03 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Immunogens and vaccine compositions against hiv
WO2025072797A2 (en) * 2023-09-27 2025-04-03 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Immunogens and vaccine compositions against hiv

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US20030096778A1 (en) * 2002-06-13 2003-05-22 Shiver John W Polynucleotide vaccines expressing codon optimized hiv-1 nef and modified hiv-1 nef
US7655774B2 (en) 2000-02-18 2010-02-02 University Of Washington Ancestral and COT viral sequences, proteins and immunogenic compositions
JP2003523188A (ja) 2000-02-18 2003-08-05 ユニバーシティ・オブ・ワシントン Ａｉｄｓ先祖ウイルスおよびワクチン
US6733993B2 (en) * 2000-09-15 2004-05-11 Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications
EP1331942A4 (en) 2000-09-22 2005-03-16 Univ Duke Immunogenic with ligand-bound HIV envelope protein
US7172761B2 (en) 2001-11-07 2007-02-06 Duke University Polyvalent immunogen
CA2539325C (en) 2003-09-17 2016-03-22 Duke University Consensus/ancestral immunogens
US8048431B2 (en) 2003-09-17 2011-11-01 Duke University Modified HIV-1 clade C envelope glycoprotein immunogens comprising deletions in the gp120/gp41 cleavage site and gp41 fusion domain
HRP20040589B1 (en) 2004-06-28 2011-07-31 Biljan Marijan The stand for garment hangers with a built-in counter

Also Published As

Publication number Publication date
AU2004274937B2 (en) 2011-03-24
EP1667714B1 (en) 2018-01-03
CA2539325C (en) 2016-03-22
US8071107B2 (en) 2011-12-06
JP2014079250A (ja) 2014-05-08
KR20070028291A (ko) 2007-03-12
WO2005028625A3 (en) 2005-06-02
IL230011A0 (en) 2014-01-30
CA2918585C (en) 2019-05-21
KR20120086379A (ko) 2012-08-02
US20180296665A1 (en) 2018-10-18
CN1852734B (zh) 2010-12-01
JP2007505624A (ja) 2007-03-15
US9844589B2 (en) 2017-12-19
AU2004274937A1 (en) 2005-03-31
HK1097446A1 (en) 2007-06-29
US20070178562A1 (en) 2007-08-02
EP1667714A4 (en) 2008-09-24
JP4773352B2 (ja) 2011-09-14
CA2539325A1 (en) 2005-03-31
CN102010463A (zh) 2011-04-13
CA2918585A1 (en) 2005-03-31
JP6165612B2 (ja) 2017-07-19
EP2371387A2 (en) 2011-10-05
AU2004274937B9 (en) 2011-04-14
EP2371387A3 (en) 2012-01-25
EP1667714A2 (en) 2006-06-14
WO2005028625A2 (en) 2005-03-31
JP2011136997A (ja) 2011-07-14
US10946090B2 (en) 2021-03-16
CN1852734A (zh) 2006-10-25
AU2004274937A2 (en) 2005-03-31
IL174380A0 (en) 2006-08-01
US20120087938A1 (en) 2012-04-12
IL202249A (en) 2015-08-31

Similar Documents

Publication Publication Date Title
BRPI0414443A (pt) imunógenos consensuais/ancestrais
MX9203458A (es) Segmentos inmunogenicos que contienen glicoproteinas quimericas de las glicoproteinas de virus sincitial respiratorio humano.
AU2003244855A1 (en) Method to enhance an immune response of nucleic acid vaccination
WO2004007679A3 (en) Dendritic cell pontentiation
ATE527281T1 (de) Impfstoffe gegen aids umfassend cmv/r nucleinsäurekonstrukte
DK1326961T3 (da) Sammensætninger og fremgangsmåder tl inducering af specifikke cytolytiske T-cellereaktioner
DE60139542D1 (de) Methoden zur herstellung humaner monoklonaler antikörper
NO20072733L (no) Doseformer
NO20031646L (no) Adjuvanssammensetning omfattende et immunostimulatorisk oligonukleotid og en tokol
DK1448229T3 (da) Farmaceutisk sammensætning til at inducere et immunrespons hos et menneske eller et dyr
BRPI0619595A8 (pt) anticorpo neutralizante, epítopo, seqüência de dna isolada, vetor de clonagem ou expressão, célula hospedeira, processo para a produção de um anticorpo, composição farmacêutica, e, uso de um anticorpo neutralizante humanizado ou completamente humano
ES8900007A1 (es) Un metodo para producir normas orales frente a virus de hepatitis-b.
BR9712556A (pt) Plasmìdeo, composição farmacêutica, e, processo de imunizar um indivìduo contra um antìgeno
BR0309963A (pt) Proteìna de fusão das proteìnas reguladoras/acessórias do hiv
TW200517121A (en) Immunogen
DE602004027251D1 (de) Herstellung von 1,3-diphenylprop-2-en-1-onderivaten
ES8708250A1 (es) Un procedimiento para producir glucagon o fragmentos o derivados del mismo en levadura
DK0973544T3 (da) Immuntolerant prothrombinkomplekspræparat
GB9814538D0 (en) Helicobacter pylori bacterioferritin
TW200726479A (en) Method of inducing neutralizing antibodies to human immunodeficiency virus
BR0312808A (pt) Proteìna de fusão igg fc/hiv-gp120/c3d
DK1093465T3 (da) Fremgangsmåde til frembringelse eller forögelse af en T-cellerespons mod en målcelle ved brug af kompleks omfattende et HLA klasse I molekyle og et tilkoblingsorgan
WO2000008043A3 (en) Prevention and treatment of viral disease
NO20062081L (no) Fremgangsmate
DK1416956T3 (da) Autologe T-celle-vaccinematerialer samt fremgangsmåde til deres fremstilling

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2324 DE 21-07-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.